Hippocratic AI, the company building the first safety-focused Large Language Model (LLM) for healthcare, today announced the establishment of its Healthcare Advisory Board and its members. The board's purpose is to help guide the company on broad issues in the healthcare industry, including economics, governmental policy, risk management, research, and macro-level trends. This board complements Hippocratic AI's Physician and Nurse Advisory Councils, which provide primarily clinical and workforce-specific input to the company. The inaugural members of the Hippocratic AI Healthcare Advisory Board are: Scott Becker – Founder, Publisher, and Chief Content Officer of Beckers Healthcare, a

Issued on behalf of Avant Technologies Inc. USA News Group News Commentary  VANCOUVER, BC, Nov. 12, 2024 /PRNewswire/ -- Recently the World Economic Forum released a report that highlights AI's potential to relieve pressure on healthcare systems worldwide, with Mayo Clinic's early adoption showing how AI can drive progress. Elon Musk has also hinted that his company's Grok AI could have applications in medical image analysis. At this year's HLTH conference in Las Vegas, tech giants like Nvidia, Google, and Microsoft presented their latest AI healthcare tools. Meanwhile, a range of emerging tech companies are making strides in AI-powered healthcare, including: Avant Technologies, Inc. (OTCQB:

Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co

FRANKLIN, Tenn., Oct. 29, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced its participation in the following investor conferences: CFO, Peter Kuipers, will present at the 2024 UBS Global Healthcare Conference on Tuesday, November 12, 2024, at 5:00 p.m. Eastern Time.CFO, Peter Kuipers, will participate in the Canaccord Genuity 2024 Medical Technology, Diagnostics, and Digital Health & Services Forum on Thursday, November 21, 2024.CEO, Andrew Toy, will participate in the Virtual BTIG Digital Health Forum on Monday, November 25, 2024.CFO, Peter Kuipers, will present at the 2024 Citi Global Healthcare Confer

FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results. Third Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Third Quarter 2024 Earnings Conference CallWhen: Wednesday, November 6, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1

FRANKLIN, Tenn., Oct. 15, 2024 (GLOBE NEWSWIRE) -- Clover Health (NASDAQ:CLOV) ("Clover" or "the Company") has announced the debut of its 2025 Medicare Advantage (MA) plan offerings in New Jersey. Clover offers a range of affordable and flexible healthcare options for Medicare beneficiaries, which are designed to meet the unique needs of New Jersey seniors, especially those on fixed incomes facing rising costs of living. For full plan details, availability, and eligibility visit https://www.cloverhealth.com/plans. "We are proud to reaffirm our commitment to New Jersey by maintaining our affordable benefit-rich PPO plans for 2025," said Jamie Reynoso, Clover's CEO of Medicare Advantage. "

FRANKLIN, Tenn., Oct. 10, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that the Centers for Medicare and Medicaid Services ("CMS") has increased the Star rating of its PPO Medicare Advantage ("MA") plans to 4 Stars for 2025, which will affect payment year 2026. Additionally, CMS increased the rating of Clover's HMO MA plan to 3.5 Stars. Currently, over 95% of Clover's Medicare Advantage membership is served through its PPO plans. Each year CMS rates every plan on its healthcare quality and drug plan, and issues a Star rating on a scale of 1 to 5 Stars. For this measurement year, Clover's overall S

FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation

FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

10-Q - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

8-K - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Filer)

The recent insider purchase at Clover Health Investments Corp. by Director Garipalli Vivek on June 20, 2024, has caught the attention of investors. Director Garipalli Vivek bought $1,000,426 worth of shares, acquiring 877,567 units at $1.14 per share, as reported in SEC Form 4. This insider purchase stands out among recent insider transactions at Clover Health. Looking at the previous transactions, there have been instances of insiders covering exercise/tax liability by selling shares, resulting in a decrease in their direct ownership percentages. For example, Reynoso Jamie L., Priest Brady Patrick, Toy Andrew, Sharp Aric R, Soares Karen, Chief Technology Officer Wai Conrad, and CEO Reynoso

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

4 - CLOVER HEALTH INVESTMENTS, CORP. /DE (0001801170) (Issuer)

UBS initiated coverage of Clover Health with a rating of Neutral and set a new price target of $4.00

SVB Leerink reiterated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $2.50 from $3.00 previously

Cowen & Co. upgraded Clover Health Investments from Underperform to Market Perform and set a new price target of $3.00 from $7.00 previously

Canaccord Genuity initiated coverage of Clover Health with a rating of Buy and set a new price target of $6.00

SVB Leerink initiated coverage of Clover Health Investments with a rating of Market Perform and set a new price target of $3.00

Citigroup resumed coverage of Clover Health with a rating of Neutral and set a new price target of $3.50 from $9.00 previously

Credit Suisse downgraded Clover Health from Neutral to Underperform and set a new price target of $3.50 from $9.00 previously

Credit Suisse reiterated coverage of Clover Health Investments with a rating of Neutral and set a new price target of $9.00 from $8.00 previously

Cowen & Co. initiated coverage of Clover Health Investments with a rating of Underperform and set a new price target of $7.00

Citigroup resumed coverage of Clover Health with a rating of Neutral and set a new price target of $10.00

FRANKLIN, Tenn., Oct. 08, 2024 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. ("Counterpart"), a leading AI-powered physician enablement platform, today announced the appointment of David Tsay M.D., Ph.D as Chief Medical Officer (CMO). Dr. Tsay will play a key role in advancing Counterpart's clinical strategy and product roadmap for Counterpart Assistant, the company's proprietary AI-powered physician enablement software platform that empowers providers to deliver high-quality, cost-effective care. Counterpart is a subsidiary of Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"). David Tsay is a distinguished physician executive with deep expertise and over two decades of ex

FRANKLIN, Tenn., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health" or "Clover"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Joseph Brand as Chief Operating Officer (COO) for its Medicare Advantage (MA) plan. Mr. Brand will oversee core MA operations and drive performance improvements, with a focus on improving healthcare delivery in New Jersey by leveraging operational efficiencies and technological innovation. Mr. Brand brings nearly 20 years of healthcare leadership experience, having held prominent positions in healthcare operation

FRANKLIN, Tenn., Aug. 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced it has appointed Thomas L. Tran to the Company's Board of Directors (the "Board"), and as a member of the Audit Committee. "Tom Tran's appointment to our Board marks a significant enhancement to our strategic financial planning and execution capabilities. With his impressive track record at the helm of finance at public managed care organizations, Tom is uniquely qualified to help guide Clover Health as we advance o

FRANKLIN, Tenn., April 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement technology company, today announced the appointment of Peter Kuipers as Chief Financial Officer ("CFO"), effective as of the day after the filing of the Company's Quarterly Report on Form 10-Q for the quarter-ended March 31, 2024. With a wealth of experience and a proven track record in financial management, Mr. Kuipers will drive strategic financial initiatives around profitability, growth and potential new revenue streams. Recognized with the 2018 San Francisco Bay Area Public Company CFO of the Year Award for small to me

FRANKLIN, Tenn., March 07, 2024 (GLOBE NEWSWIRE) -- Today Clover Health ("Clover" or "the Company") announced Clay Thornton as the newly appointed Chief Financial Officer of its Medicare Advantage (MA) division. Thornton, with an impressive track record spanning over a decade of healthcare financial management and operational leadership, joins as the Company enters the next phase of its lifecycle, targeting Adjusted EBITDA profitability for the full-year 20241, while emphasizing a differentiated PPO-first product strategy supported by its state-of-the-art technology and care management platform. Thornton's expertise in driving financial strategies that bolster quality outcomes, member and

FRANKLIN, Tenn., Nov. 01, 2023 (GLOBE NEWSWIRE) -- Clover Health (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced the appointment of Karen Soares as General Counsel, effective October 31, 2023. Karen will serve on Clover's management team and will report to Andrew Toy, Chief Executive Officer of Clover. "Karen has been a tremendous asset to Clover over the years, providing strategic legal counsel and partnership as our business has continued to evolve. I'm delighted to have her serve as our General Counsel, as Clover will benefit from her healthcare exper

FRANKLIN, Tenn., Nov. 30, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Anna Loengard, M.D. to the Company's Board of Directors. Dr. Loengard is a highly accomplished physician executive with significant experience in both geriatric medicine and value based care models. She most recently served as Chief Medical Officer of AccentCare, an enterprise providing home health, hospice, and private care services across 31 states. Previously, Dr. Loengard served as Chief Medical Officer for Caravan Health, Chief

FRANKLIN, Tenn., July 26, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Carladenise Armbrister Edwards, Ph.D., to the Company's Board of Directors. Dr. Edwards is an accomplished healthcare executive with nearly three decades of healthcare, nonprofit and government experience. Currently the Henry Ford Health System's Executive Vice President and Chief Strategy Officer, she leads the system's strategic planning efforts and partnership ventures, business development and transformation initiatives, governme

FRANKLIN, Tenn., May 09, 2022 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover" or "Clover Health"), a physician enablement company committed to improving health equity for seniors, today announced the appointment of Aric Sharp as Chief Executive Officer ("CEO") of Value Based Care for Clover. Sharp will spearhead all value based care operations for the company including for Clover Health Partners, Clover's Direct Contracting Entity ("DCE"). Sharp is recognized as a national leader on the healthcare transition to value, innovation, and physician practice management and is Chair-Elect of the American Medical Group Association. In his former role as Senior Vice Pr

Clover Health Investments's (NYSE:CLOV) short percent of float has fallen 7.26% since its last report. The company recently reported that it has 35.32 million shares sold short, which is 8.81% of all regular shares that are available for trading. Based on its trading volume, it would take traders 7.88 days to cover their short positions on average. Why Short Interest Matters Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope that the price will fall. Traders make money from short selling if the price of the stock falls and they lose if it rises. S

U.S. stock futures were mostly higher this morning, with the Dow futures gaining around 100 points on Monday. Shares of RXO, Inc.. (NYSE:RXO) shares rose sharply in today's pre-market trading after the company inked a definitive agreement to acquire Coyote Logistics from United Parcel Service, Inc. (NYSE:UPS) for $1.025 billion in cash. As per the terms, the transaction disclosed on Sunday will be financed through a combination of equity and debt, including a $300 million equity investment from MFN Partners and a $250 million equity investment from Orbis Investments, both significant shareholders of RXO. RXO shares jumped 13.3% to $22.90 in pre-market trading. Here are some big s

https://www.statnews.com/2024/06/21/medicare-coverage-wegovy-weight-loss-cancer-blood-tests-grail/

Shares of Kaival Brands Innovations Group, Inc. (NASDAQ:KAVL) fell sharply during Friday's session after the company announced pricing of $6.0 million public offering. Kaival Brands priced its 3,921,500 unit offering at $15.3 per unit. Kaival Brands Innovations Group shares dipped 47% to $1.52 on Friday. Here are some other stocks moving in today’s mid-day session. Gainers American Rebel Holdings, Inc. (NASDAQ:AREB) shares jumped 161% to $0.8048 after the company signed a Connecticut distribution agreement with Dichello Distributors. Sharecare, Inc. (NASDAQ:SHCR) jumped 74% to $1.35 after the company agreed to be acquired by Altaris affiliate for $1.43 per share in cash.

Clover Health Investments, Corp. (NASDAQ:CLOV) shares are trading higher Friday after a company co-founder purchased more than $1 million worth of shares.  The Details: Clover Health filed a Form 4 with the SEC showing that co-founder and executive chair Vivek Garipalli purchased 877,567 shares of Clover Health stock at an average price of $1.14 per share. Previously, Clover Health director Anna Loengard acquired a total of 27,085 shares at an average price of $0.94 at the end of May following better-than-expected first-quarter financial results. Related News: Why EV Maker Nikola’s Stock Is Crashing The company announced in May that its clinical decision support tool, Clover A

U.S. stocks were mixed, with the Dow Jones index gaining around 50 points on Friday. Shares of Asana, Inc. (NYSE:ASAN) rose sharply during Friday's session after the company announced a $150 million share repurchase program and reaffirmed its forward guidance. Asana said its board of directors approved a stock repurchase program authorizing the company to repurchase up to $150 million of its Class A common stock through June 30, 2025. Asana shares jumped 13.4% to $12.90 on Friday. Here are some other big stocks recording gains in today’s session. Sarepta Therapeutics, Inc. (NASDAQ:SRPT) shares jumped 39.2% to $171.89 after the company announced FDA approval of an expansion to

SRPT: 45% | Sarepeta Therapeutics shares are trading higher after the company announced FDA approval of an expansion to the labeled indication for ELEVIDYS to include individuals with Duchenne muscular dystrophy with a confirmed mutation in the DMD gene who are at least 4 years of age. Also, multiple firms raised their respective price targets on the stock. CLOV: 13% | Clover Health shares are trading higher following the purchase of 877,567 shares by a company director. NVNO: 16% | EnVVeno Medical shares are trading higher after the company reported interim venous ulcer healing data from the SAVVE U.E. pivotal trial for VenoValve, which will be presented at the Society for Vascular Surger

Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) rose sharply in today's pre-market trading after the company announced expanded US FDA approval of ELEVIDYS to Duchenne Muscular Dystrophy patients ages 4 and above. Sarepta Therapeutics shares climbed 35.2% to $166.96 in pre-market trading. Here are some other stocks moving in pre-market trading. Gainers Spectaire Holdings Inc (NASDAQ:SPEC) rose 110% to $0.7140 in pre-market trading after the company announced a purchase order and delivery of its advanced AireCore units to American Ag Energy. DermTech, Inc. (NASDAQ:DMTK) gained 105.5% to $0.2423 in pre-market trading after declining 19% on Thursday. DermTech recently filed f

The Dow Jones index closed higher by around 300 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company’s prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision. Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga’s insider transactions platform. Vaxart The Trade: Vaxart, Inc. (NASDAQ:VXRT) Director W. Mark Watson bought a total of 20,000 shares at an average price of $0.68. To acquire these shares, it cost around $13,578. What's Happening: Vaxart announced Monday that proceeds from

Delivers 9% Total Revenue growth year-to-date compared to prior year period Company improves 2024 year-to-date GAAP Net Loss from Continuing Operations by $117.4 million year-over-year and year-to-date Adjusted EBITDA by $87.2 million year-over-year Increases Full-Year 2024 guidance midpoint to target updated range of Adjusted EBITDA profitability of $55 million - $65 million, strongly positioning the Company to invest in membership growth opportunity for 2025 FRANKLIN, Tenn., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today reported financial results for the third quarter 2024. Management will host a co

FRANKLIN, Tenn., Oct. 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), today announced that it will report third quarter 2024 financial results after market close on Wednesday, November 6, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2024, to discuss Clover Health's third quarter 2024 business and financial results. Third Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Third Quarter 2024 Earnings Conference CallWhen: Wednesday, November 6, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1

Total Revenue growth for the Second Quarter of 2024 of 11% year-over-year GAAP Net Income from Continuing Operations during the Second Quarter of 2024 of $7.2 million versus Second Quarter 2023 GAAP loss of $28.9 million Adjusted EBITDA profitability for the Second Quarter of 2024 of $36.2 million versus Second Quarter 2023 Adjusted EBITDA of $9.9 million Increases Full-Year 2024 guidance to Insurance Revenue of $1.35 billion - $1.375 billion and Adjusted EBITDA profitability of $50 million - $65 million FRANKLIN, Tenn., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enab

FRANKLIN, Tenn., July 22, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover Health"), a physician enablement technology company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report second quarter 2024 financial results after market close on Monday, August 5, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on August 5, 2024, to discuss Clover Health's business and financial results. Second Quarter 2024 Conference Call and Webcast Details: What: Clover Health's Second Quarter 2024 Earnings Conference CallWhen: Monday, August 5, 2024, at 5:00 p.m. Eastern TimeDial I

First Quarter 2024 Insurance Revenue growth of 8% year-over-year First Quarter 2024 GAAP Net Loss from Continuing Operations of $23.2 million versus First Quarter 2023 loss of $79.7 million First Quarter Adjusted EBITDA profitability of $6.8 million versus prior period loss of $37.5 million Improves 2024 guidance to Insurance Revenue of $1.30 billion - $1.35 billion and Adjusted EBITDA profitability of $10 million - $30 million Maintains strong liquidity position and view that Company has sufficient capital for operating and growth needs. Board of Directors authorizes share repurchase program of up to $20 million of the Company's Class A Common Stock over the next two years FRANKLIN, Te

FRANKLIN, Tenn., April 23, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report first quarter 2024 financial results after market close on Tuesday, May 7, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on May 7, 2024, to discuss the Company's business and financial results. First Quarter 2024 Conference Call and Webcast Details: What: Clover Health First Quarter 2024 Earnings Conference CallWhen: Tuesday, May 7, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-579-2543 (for U.S. callers) or 785-424-1789 (for calle

Full-year 2023 Insurance MCR improved to 81.2% and fourth quarter MCR to 82.4% Company improves full-year 2023 Net Loss by $126.2 million and full-year Adjusted EBITDA by $245.7 million year-over-year Issues 2024 guidance with Insurance MCR range of 79% - 83% and up to $20 million of Adjusted EBITDA profitability at the high end of the range FRANKLIN, Tenn., March 12, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a managed care company focused on physician enablement, today reported financial results for the fourth quarter and full year 2023. Management will host a conference call today at 5:00 p.m. ET to discuss it

FRANKLIN, Tenn., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), today announced that it will report fourth quarter and full year 2023 financial results after market close on Tuesday, March 12, 2024. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on March 12, 2024 to discuss the Company's business and financial results. Fourth Quarter and Full Year 2023 Conference Call and Webcast Details: What: Clover Health Fourth Quarter and Full Year 2023 Earnings Conference CallWhen: Tuesday, March 12, 2024, at 5:00 p.m. Eastern TimeDial In: To access the call via telephone please dial 800-57

Q3 2023 Insurance MCR Improved to 78.5%, bringing year-to-date MCR to 80.8%, and Insurance revenue grew 12% compared to Q3 2022 Company reports Q3 2023 Net Loss of $41.5 million and Adjusted EBITDA loss of $5.1 million Revised full-year 2023 guidance now reflects Insurance MCR of 81% - 82% and Adjusted EBITDA of ($55) million - ($80) million FRANKLIN, Tenn., Nov. 06, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today reported financial results for the third quarter 2023. Management will host a conference call t

FRANKLIN, Tenn., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Clover Health Investments, Corp. (NASDAQ:CLOV) ("Clover," "Clover Health" or the "Company"), a physician enablement company committed to bringing access to great healthcare to everyone on Medicare, today announced that it will report third quarter 2023 financial results after market close on Monday, November 6, 2023. Management will host a conference call and webcast at 5:00 p.m. Eastern Time on November 6, 2023 to discuss the Company's business and financial results. Third Quarter 2023 Conference Call and Webcast Details: What: Clover Health Third Quarter 2023 Earnings Conference CallWhen: Monday, November 6, 2023, at 5:00 p.m. Eastern